Modulation of hyperoxia-induced TNF-α expression in the newborn rat lung by thalidomide and dexamethasone

Inflammation

Volumn 24, Issue 4, 2000, Pages 347-356

  Lindsay, Learie ^a   Oliver, Stephen J ^b   Freeman, Sherry L ^b   Josien, Regis ^b   Krauss, Alfred ^a   Kaplan, Gilla ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; OXYGEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG EFFECT; HYPEROXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG INJURY; LUNG LAVAGE; NONHUMAN; RAT;

ANIMALS; ANIMALS, NEWBORN; BRONCHOALVEOLAR LAVAGE FLUID; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HYPEROXIA; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LUNG; MACROPHAGES, ALVEOLAR; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0034041565     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007096931078     Document Type: Article

References (20)

1. 1. National Center for Health Statistic. Health United States 1991 and Prevention Profile Hyattsville, Maryland: Public Health Service, 1992.
2. 2. NORTHWAY, W. H., JR. 1992. Bronchopulmonary dysplasia: twenty-five years later. Pediatrics, 89:969-973.
3. 3. CONTRERAS, M., N. HARIHARAN, J. R. LEWANDOSKI, W. CIESIELSKI, R. KOSCIK, and J. J. ZIMMERMAN, 1996. Bronchoalveolar oxyradical inflammatory elements herald bronchopulmonary dysplasia. Crit. Care Med., 24:29-37.
4. 4. MUSTAFA, M. G., and D. F. TIERNEY. 1978. Biochemical and metabolic changes in the lung with oxygen, ozone, and nitrogen dioxide toxicity. Am. Rev. Respir. Dis., 118:1061-90.
5. 5. FANTONE, J. C., and P. A. WARD. 1982. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am. J. Pathol., 107:395-418.
6. 6. TAKASUKA, N., K. MATSUURA, S. YAMAMOTO, and K. S. AKAGAWA. 1995. Suppression of TNF-α mRNA expression in LPS-primed macrophages occurs at the level of nuclear factor-κB activation, but not at the level of protein kinase C or CD14 expression. J. Immunol., 154:4803-4812.
7. 7. SCHRECK, R., P. RIEBER, and P. A. BAEUERLE. 1997. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. Embo. J., 10:2247-2258.
8. 8. MARCHO, Z., J. E. WHITE, P. J. HIGGINS, and M. F. TSAN. 1992. Tumor necrosis factor enhances endothelial cell susceptibility to oxygen toxicity: role of glutathione. Am. J. Respir. Cell. Mol. Biol., 5:556-562.
9. 9. SATO, N., T. GOTO, K. HARANAKA, N. SATOMI, H. NARIUCHI, Y. MANO-HIRANO, and Y. SAWASAKI. 1986. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphological modulation, growth inhibition, and cytotoxicity. J. Natl. Cancer Inst., 76:1113-1121.
10. 10. ROYALL, J. A., R. L. BERKOW, J. S. BECKMAN, M. K. CUNNINGHAM, S. MATALON, and B. A. FREEMAN. 1989. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol., 257:L399-410.
11. 11. STOLPEN, A. H., E. C. GUINAN, W. FIERS, and J. S. POBER. 1986. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am. J. Pathol., 123:16-24.
12. 12. SHALABY, M. R., B. B. AGGARWAL, E. RINDERKNECHT, L. P. SVEDERSKY, B. S. FINKLE, and M. A. PALLADINO, JR. 1985. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J. Immunol., 135:2069-2073.
13. 2 toxicity: role of endogenous tumor necrosis factor. Exp. Lung Res., 21:589-597.
14. 14. GIBBS, L. S., L. LAI, and A. B. MALIK. 1990. Tumor necrosis factor enhances the neutrophil-dependent increase in endothelial permeability. J. Cell Physiol., 145:496-500.
15. 15. HORINOUCHI, H., C. C. WANG, K. E. SHEPHERD, and R. JONES. 1996. TNF alpha gene and protein expression in alveolar macrophages in acute and chronic hyperoxia-induced lung injury. Am. J. Respir. Cell Mol Biol., 14:548-555.
16. 16. CARP, H., and A. JANOFF. In vitro suppression of serum elastase-inhihitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes. J. Clin. Invest., 63:793-717.
17. 17. ZIMMERMAN, J. J. 1995. Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia. Clin. Perinatol., 22:429-456.
18. 18. CORRAL, L. G., G. W. MULLER, A. L. MOREIRA, Y. CHEN, M. Wu, D. STIRLING, and G. KAPLAN. 1996. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med., 2:506-515.
19. 19. MOREIRA, A. L., E. P. SAMPAIO, A. ZMUIDZINAS, P. FRINDT, K. A. SMITH, and G. KAPLAN. 1993. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med., 177:1675-1680.
20. 20. SAMPAIO, E. P., E. N. SARNO, R. GALILLY, Z. A. COHN, and G. KAPLAN. 1991. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., 173:699-703.